Ana Sofia Cerdeira

Retaining Fee Lecturer

I am a clinician scientist with a particular interest in pre-eclampsia and angiogenic factors.

We recently conducted the first clinical trial on the use of sFlt-1/PlGF ratio in the management of patients with suspected pre-eclampsia (Cerdeira AS et al. Hypertension 2019). Data from our study and previous observations lead to the development of a protocol that is now used in clinical practice. My aim is to continue exploring the role of angiogenic factors in the prediction, diagnosis and treatment of pre-eclampsia, hopefully leading to meaningful changes in patient care.



‘Randomized Interventional Study on Prediction of Preeclampsia/Eclampsia in Women With Suspected Preeclampsia.’
Cerdeira AS. et al, (2019), Hypertension (Dallas, Tex. : 1979),

‘Taming preeclampsia at its source’
Cerdeira AS. and Vatish M., (2018), Nature Biotechnology, 36, 1151 – 1152

‘Performance of soluble fms-like tyrosine kinase-1–to–placental growth factor ratio of ≥85 for ruling in preeclampsia within 4 weeks’
Cerdeira AS. et al, (2021), American Journal of Obstetrics and Gynecology, 224, 322 – 323

‘In vivo evidence of significant placental growth factor release by normal pregnancy placentas’
Cerdeira AS. et al, (2020), Scientific Reports, 10

Where Next?